Autopsy records of 151 patients dying of acute myocardial infarction, in a large private hospital, were reviewed. Half of the patients received anticoagulant therapy. Hemorrhage was not a significant cause of death in Dicumarol-treated patients. Embolic complications, often undiagnosed clinically, were of common occurrence. Adequate anticoagulant therapy effectively reduced, not only the total number of emboli, but also the number of serious or fatal emboli. In this role, anticoagulants serve a useful purpose in the treatment of myocardial infarction.
E ARLY optimism regarding the effectiveness of anticoagulant therapy in patients with myocardial infarction has been tempered by changing concepts of the mortality in this disease, by the risk of hemorrhage attending their use, and by the difficulty in clinical appraisal of any therapeutic agent in a disease characterized by great variability.1'5 Although thousands of cases are included in the clinical data, with few exceptions autopsy material has not been utilized to study the effects of these drugs.5-8 It is known that death in myocardial infarction may result from shock, congestive failure, arrhythmia, embolization, or ventricular rupture. These multiple factors influence the prognosis of the patient in diverse ways so that a clinical appraisal of one factor, thromboembolism, and its role in mortality and morbidity has been difficult to assess. With reliance solely on clinical data, it is even more difficult to determine the efficacy of anticoagulant therapy in preventing these complications of myocardial infarction. The present The present series of 151 autopsied cases was collected from a private general hospital with an active service in cardiovascular disease. All records were obtained from patients admitted between January 1, 1946 , and December 31, 1953, inclusive. This eight-year period was selected for 2 reasons: first, records classified by the "unit" system were easily obtained, and second, during this interval a standard anticoagulant data sheet had been utilized for all patients receiving the drugs. The daily dosage, the prothrombin response, and the complications of therapy were thus clearly indicated on all records.
The clinical diagnosis of myocardial infarction was made in 960 instances during this period. This figure included, not only those dying shortly after admission, but also those dead on arrival to the hospital in whom the diagnosis was often presumptive. Of the patients admitted with this diagnosis 316 (32 per cent) died and 193 autopsy records (61 per cent) were available. Forty-two records were discarded because the patient had survived in the hospital less than 24 hours and the data were therefore incomplete. One hundred fifty-one suitable (76) * (72) (4) (75) (49) (26) * In parenthesis, total number in that category.
t Generalized vascular sclerosis, gastric hemorrhage, ruptured ventricle, ruptured aneurysm, diabetes, uremia, pulmonary emboli.
Seventy-six per cent of patients receiving the drugs, as well as 76 per cent of those not given anticoagulant therapy, were attended by internists. The remainder of the patients in both groups were seen either by general practitioners or on the service wards of the hospital. Consultation was widely used in the latter two categories.
Autopsies were performed by or under the direction of two senior pathologists,* thus insuring uniform interpretation of pathologic material. For the most part, the autopsies were completed independent of the present investigation, so that the pathologic findings were unbiased by the present study. CHARACTER OF THE SAMPLE-CLINICAL  ANALYSIS  The final clinical discharge diagnoses at  death are summarized in table 1 . Seventy-six patients receiving any form of anticoagulant therapy were included in the "treated" group. The "untreated" consisted of 75 in whom no such drugs were administered.t A discrepancy existed between the clinical and pathologic diagnosis in 26 of the "untreated" and 4 of the "treated" patients. Since the diagnoses were often more obscure in the "untreated" group, it is clear that the two groups were not selected completely at random (P = <.001).9 Nevertheless, it is possible to compare the groups in a number of their clinical and pathologic attributes, once these differences in the samples are recognized.
The clinical features of the two groups are presented in table 2. The two groups were similar in regard to age, race, sex, obesity, the presence of failure, arrhythmia, history of previous occlusion, and the finding of shock. The mean age of the "treated" group was 62.2 years, of the "untreated" 64.9. Figure 1 shows the similar age distribution of the two groups by three-year intervals. A high incidence of failure characterized both groups (table 2) . Serious arrhythmias were likewise of common occurrence in both groups (table 2) . These included atrial fibrillation or flutter, frequent atrial or ventricular extrasystoles, various degrees of heart block, and ventricular tachycardia or fibrillation.
The duration of illness from onset of symptoms to death is plotted in figure 2 . Twenty-two patients in whom emboli were a primary cause of death, or a major contributing cause of death (as determined by pathologic study) have been plotted separately. Six of these deaths occurred in "treated" patients, 16 in "untreated" patients. The time-mortality curves for the three groups are similar. By the tenth day of hospitalization half of all the t The similarity in numbers of the 2 groups is fortuitous. The (table 4) . Although a portion of the failure might be ascribed to terminal pulmonary edema, the incidence of failure was higher in both groups thaii the (linical data had suggested.
Clinically, hypertension was comnimoner in the "treated" group. Cardiac hypertrophy however, one objective reflection of sustained hypertension, was of equal distribution ini both groups ( fig. 3 ). Likewise the incidence of a previous occlusion was greater in both groups than the history had indicated, since it was found at autopsy in 30 of the "tIeated" and 27 of the "untreated" patients.
Aneurysmal dilatation of the left vent ricle resulting from a previous infarct was found in .) of the "untreated" and in 12 of the "treated" patients (P = .1-.0A5). Old mural thrombi in asso(iation with the aneurysm were found in 3 of the former and 7 of the latter categories, which confirm the findings of Schlichter, Hellersteini, and Katz regarding the frequency of this complication in patients with myocardial inifar(ction.10
A definite thrombotic corollary occlusion In parentheses are the number of patients in that category. When only the presence or absence of mural thrombosis is considered, the probability is between .01-.001 that the differences in the three groups are due to chance alone. 44 14 17 16 In parentheses are the number of patients in that treatment category.
When only the presence or absence of embolization is considered, the probability is less than .001 that the differences in the three groups are due to chance alone.
* "Primary"-emboli as a primary cause of death or major contributing cause of death. (See text.) The probability is between .01 and .001 that the differences in the 3 groups are due to chance alone.
"treated" patients. The remainder of the coronary thrombi were found in various combinations. THROMBOEMBOLIC COMPLICATIONS AS AFFECTED BY ANTICOAGULANT THERAPY Mural Thrombi
Mural thrombi, visible grossly, were significantly reduced by adequate therapy. They were present in 13 of the "adequately treated" group, while 31 in the "untreated" group showed this complication. Inadequate therapy, however, was of no advantage, since mural thrombi were found in 12 of 20 "inadequately treated" patients (table 5). In the "adequately treated" group, more than 1 chamber was involved in 3 cases, whereas there were 19 such instances in the "untreated" group (table 5) .
The early appearance of mural thrombi is noteworthy, occurring in a number of patients whose clinical history was brief. Twenty-two patients receiving adequate anticoagulant therapy died on or before the fifth day of illness (fig. 2) ; mural thrombi were present in 5 of them. Nineteen of the "untreated" group died in this same interval; mural thrombi were present in 7. Mural thrombi were present in 2 of 6 "inadequately treated" patients dying during this same period. Emboli A striking reduction in emboli was observed in the present series of patients receiving anticoagulant drugs. In the "untreated" group, 31 instances of such complications were noted (41 per cent); among "adequately treated" patients, 5 were found (9 per cent) ( (table 6) , 85 embolic sites being found in the "untreated" group, whereas only 6 were observed in "adequately treated" patients. The diminution in the number of emboli is important, since widely scattered, multiple emboli have a serious prognosis.
Emboli as a Major Contributing Cause of Death
The significance of the emboli in relation to the death of the patient was studied. Cases were selected in which the pathologist classified the emboli at the time of autopsy, as "primary cause of death" or "major contributing cause of death." Sixteen such patients were found in the "untreated" group (21 per cent), whereas only 2 were observed in the "adequately treated" patients (3 per cent) (table 6). Considered as an important cause of death were massive, repeated or multiple pulmonary infarcts, venous thrombosis associated with massive pulmonary infarction, extensive cerebral thrombosis or infarction, peripheral arterial or mesenteric occlusion, and multiple emboli in scattered areas. As was previously observed in regard to the number of patients affected with emboli, inadequate therapy offered no protection against this complication.
Age of Patient and Occurrence of Emboli
The relationship of age and the incidence of embolization is seen in figure 4. There was a higher incidence of emboli in patients 60 years of age and over, particularly in the "untreated" group. The diagram illustrates the marked diminution in embolic phenomena in this age group when anticoagulants were used. There were, however, 47 patients under 60 years of age in the entire group of patients studied. In these 47 patients, 10 showed emboli (21 per cent). Only 1 of the 10 patients of this combined group had received adequate anticoagulant therapy. in the "untreated" group, whereas 31 patients were found with this complication. In the "treated" group the diagnosis was correctly made in 5 of the 15 patients in whom emboli were found at autopsy. The diagnosis was usually correct when cerebrovascular or peripheral arterial occlusion occurred. Pulmonary emboli, however, were often overlooked clinically, even when obvious on gross dissection. The diagnosis was even more difficult in the presence of multiple emboli. 
Extension of Infarct or New Infarct
Four patients in the "untreated" group showed either extension of a fresh infarct upon an older infarct or a completely new infarct in association with an older one, in either case suggesting a recent extension of the coronary thrombosis with further vascular occlusion. Five of the "treated" group (4 on adequate dicumarol therapy) showed similar extension. In every instance, whether or not the patient received anticoagulant drugs, extension was always associated with profound calcification of the arteries, the lumina often being so narrowed as to be imperceptible on dissection.
Thrombophlebitis
The venous channels of the legs are a wellknown focus of emboli in patients with myocardial infarction.'3 Although dissection of the calf veins was not carried out in the present study, 6 of the patients in the "untreated" group (8 per cent) had thrombosis of the inferior vena cava or the iliac veins. No instance of thrombosis of these vessels was found in the "treated" group (P = .01-.001).14 In 5 of the 6 patients with venous thrombosis, multiple or massive pulmonary emboli were found at autopsy. Anticoagulants seemed highly effective in preventing thrombophlebitis and subsequent disastrous emboli.
Complications of Therapy: Hemorrhage, Ruptured Ventricle, and Hemorrhagic Pericarditis Table 7 summarizes the data in regard to hemorrhage. Of interest was the occurrence of hemorrhage in the "untreated" group. At autopsy, 5 (6.6 per cent) of the "untreated" group showed gross evidence of hemorrhage, while a sixth had severe nosebleeds when alive. Serious significance was ascribed to hemorrhage from duodenal ulcer in 1 of the "untreated" None of the differences is statistically signifiecant.
patients, and to a cerebral hemorrhage ill a second. Seven of the patients receiving dicumarol (9.2 per cent) showed evidence of gross hemorrhage. In 1 patient with gastric bleeding and a second with gross hematuria, the diagnosis was made clinically, and the drugs were discontinued. Microscopic hematuria often occurred with adequate anticoagulant therapy and was not regarded as a contraindication to the drug. Death was ascribed to hemorrhage in 1 "treated" patient. Massive bleeding was noted in the medulla, the large and small bowel, and the bladder. These hemorrhages were not detected clinically, nor was the prothrombin concentration excessively low during life. There is no statistical significance between the occurrence of hemorrhage in the "untreated" and "treated" group.
Five patients in the "untreated" group (6.6 per cent) and 6 receiving dicumarol (7.9 per cent) died with rupture of the left ventricle. One patient in each group was found to have hemorrhagic pericarditis without obvious rupture. A higher incidence of fibrinous pericarditis without gross hemorrhage or rupture, however, was found in the "treated" group, 7 such instances being found in the "treated" group, while 2 were found in the "untreated" (P = .A-.05).
DISCUSSIONrrhe 2 groups were similar in regard to age, heart is eight, and duration of illness. There were likewise no significant differences in regard to race, obesity, congestive failure, major arrhythmia, shock, previous infarction, extension of infarction, aneurysmal dilatation of the ventricles, or hemorrhage. Excluding emboli, the primary causes of death were similar in the 2 groups. Furthermore, even though there were observed differences in regard to sex, diabetes, and history of hypertension, the effectiveness of anticoagulant therapy in reducing embolic complications was not modified by these differences. We assume that the association between angina and diminution in emboli was fortuitous.
The incidence of thromboembolic complications in the 2 groups stands in sharp contrast to these fundamental similarities. The total number of emboli, the incidence of emboli as a primary cause of death, and the incidence of mural thrombosis were all reduced by adequate specific therapy until they were no longer major factors in the over-all mortality.
The present series of autopsied patients emphasizes the observation that patients seriously ill with myocardial infarction are prone to thromboembolic complications. These data confirm the observations of Hellerstein and Martin,15 who studied a group of autopsied patients not receiving dicumarol. They found an incidence of 26 per cent serious or fatal emboli. Miller and co-authors,'6 studied a similar group and found fatal thromboembolic complications in 14 per cent of their cases. In the collected autopsy series of Wright, Marple, and Beck5 the extra cardiac complications of myocardial infarction were reduced from 125 per 100 cases in the "untreated" to 45 per 100 patients given anticoagulants. Burton6 noted a reduction in emboli from 62 per cent of the "untreated" to 10 per cent of the "treated" cases. Gilchrist and Tulloch' found thromboembolic complications 2/4 more frequent in the "untreated" than the "treated" group. In the present series, not only were the total number of patients affected by emboli reduced with anticoagulants, but also the incidence of fatal or serious emboli was markedly diminished.
The present study indicates that anticoagulant therapy must be started early and used adequately in order to be effective. Inadequate, poorly planned therapy is no more effective in preventing emboli than no therapy whatsoever. The time-mortality curve of fatal embolization, the findings of fresh mural thrombi by the fifth day of symptoms, and the occurrence of aneurysms containing old mural thrombi forming a nidus for propagation of a new thrombosis, emphasize the urgency of early anticoagulant therapy. These observations theoretically justify the concomitant use of heparin and dicumarol on the initiation of therapy, since dicumarol is ineffective during the first few days of its use.
There is an undue risk in waiting to make a definitive diagnosis of myocardial infarction in doubtful or dubious cases. It is necessary only to recognize that the patient has a condition in which thromboembolic complications are a real hazard.7-" Without question, anticoagulant therapy diminishes the disability and death associated with embolic complications, not only in patients with myocardial infarction, but also those without infarction whose clinical status is otherwise similar.
Russek and co-authors20' 21 have recommended that patients on admission to the hospital be classified according to "good" or "bad risk" categories, reserving anticoagulant therapy only for the latter group. Schnur2 has shown that the response to any type of therapy in myocardial infarction, insofar as reduction in mortality is concerned, varies with the severity of the clinical status of the patient rather than the effect of any specific drugs. It is being recognized, however, that the prognosis of the patient cannot be made definitely, especially on admission to the hospital, particularly for the first 48 hours.22 In the present series many patients shifted from "good risk" to "bad risk" categories ( 10 days of the onset of the symptomns of myocardial infarction.
The difficulty in accurate clinical diagnosis of emboli observed in the present series of cases has been noted by Hellerstein and Martin,'5 Wright and associates,5 and others. This difficulty must be considered when it is stated that clinically emboli are uncommon in patients with myocardial infarction. ' Emboli were more frequent in the present series in patients of older age (fig. 4) In the present series adequate anticoagulant therapy failed to prevent the extension of the infarct or a new thrombosis in the coronary circulation. In the entire group with this complication, sclerosis was of such intensity that the drug appeared ineffectual. The failure of adequate anticoagulant therapy to prevent extension of infarction in the presence of severe atherosclerosis has been confirmed by the autopsy studies of Wright, Marple, and Beck.5 Thrombophlebitis of the venous channels in the extremities was diminished with anticoagulant therapy, no single instance being noted in the "treated" group. Five of the 6 patients with this complication in the "untreated" group had emboli. One of the chief contributions of anticoagulant drugs may well be their effect on venous thromboses, which are so commonly associated with cardiac disease.
The incidence of hemopericardium and rupture was higher in Wright's series of patients receiving dicumarol than in his "untreated" group.' Similar observations were made by Waldron and co-authors.24 Goldstein and Wolff25 found hemopericardium associated with fibrinous pericarditis in patients receiving dicumarol for myocardial infarction. Anderson and co-workers,26 however, reported similar findings in ] patient not receiving dicumarol. Dicumarol has produced hemopericardium when given after inyocardial trauma,27 and in patients with nonspecific pericarditis. 2" 29 In the present series, small areas of focal hemorrhage were usually observed with exudative fibrinous pericarditis. In the 2 cases of frank hemorrhagic pericarditis, however (table  7) , the area of fibrinous pericarditis was localized and well circumscribed.
The incidence of hemorrhagic complications is low, in most series." 6 In our opinion the increased risk of hemorrhage, of hemorrhagic pericarditis, and of rupture of the ventricle is less than the benefit to be obtained with the judicious use of these drugs, provided there is adequate laboratory control and clinical awareness of the risk their use entails. The present communication indicates that the chief purpose of anticoagulant therapy in acute myocardial infarction is the prevention of the thromboembolic disease that often accompanies the inifarct,. In this role, anti-coagulant drugs serve a useful purpose largely in controlling this serious complication. Their use should not divert the clinician from the problems of shock, failure, and arrhythmia, which together play a more decisive role in the final outcome of the patient. SUMMARY Autopsy records of 151 patients dying of myocardial infarction in a large private hospital were reviewed. Seventy-six patients received anticoagulant therapy, and 75 patients did not. Embolic phenomena were of common occurrence in patients dying with myocardial infarction. Clinically, these were often overlooked. The utilization of anticoagulant drugs reduced strikingly the incidence of embolic complications from 41 per cent in the "untreated" series to 9 per cent in the "adequately treated" group. Emboli responsible for the death of the patient, as judged by the pathologist, were reduced from 21 per cent in the "untreated" group to 4 per cent in patients receiving adequate therapy. Inadequate, delayed or poorly planned therapy afforded the patients no protection from this complication. Thrombophlebitis was markedly diminished in "treated" patients, and fewer mural thrombi were found in patients who received adequate therapy. Extension of the infarct or a new infarct was uninfluenced by anticoagulant drugs.
Hemorrhage in the present series was not a significant cause of death. Rupture of the ventricle was noted to occur in both groups regardless of therapy.
The patients could not be rigidly classified on admission to the hospital in regard to their eventual prognosis. This observation, plus the difficulty of diagnosis and the unpredictability of the disease, confirmed the inference that the decision to use anticoagulant therapy should not be dependent upon rigid diagnostic criteria for infarction. The benefit to be obtained from these drugs during the acute phase of illness can be ascribed to 
